After adjusting for stroke severity, statin discontinuation was still associated with poor outcome (adjusted OR, 2.4; 95% CI, 1.13-4.56) and higher mortality (adjusted OR, 2.0; 95% CI, 1.30 -3.04). However, these associations were attenuated and no longer significant after excluding patients treated palliatively. Conclusions-We found no association between preadmission statin use and outcomes in intracerebral hemorrhage. Statin discontinuation may worsen outcomes or may simply be a marker of worse underlying prognosis. (Stroke. 2012;43:00-00.)
T
here is increasing interest in HMG-CoA reductase inhibitors (statins) as a neuroprotective agent after stroke, including intracerebral hemorrhage (ICH). Potentially beneficial pleiotropic effects of statins include endothelial stabilization, antithrombotic properties, anti-inflammatory actions, and upregulation of endothelial nitric oxide synthase. Experimental models of ICH suggest that statins improve outcome. 1, 2 However, data from human studies have been somewhat conflicting. Several studies have suggested that patients taking statins before ICH have better outcomes [3] [4] [5] [6] [7] whereas 2 studies did not, including a relatively large cohort of 629 patients. 8, 9 Limitations of prior studies include that they are mostly from single centers, [3] [4] [5] [7] [8] [9] have not always reported postdischarge outcomes, [5] [6] [7] have not adjusted for confounding by limitation of care orders, [3] [4] [5] [6] [7] [8] [9] and have not accounted for the potential influence of statin discontinuation. [3] [4] [5] [6] [7] [8] Experimental models suggest that sudden cessation of statin medications results in suppression of endothelial nitric oxide synthase, 10 generation of superoxide anions, 11 impaired endothelial relaxation, 11 and loss of ischemic protection and thrombus inhibition. 12 Human studies also suggest that discontinuation of statins may worsen clinical outcomes after cardiovascular events, possibly by increasing inflammatory activity, 13 periinfarct edema, 14 and infarct volume. 15 The primary objective of our study was to determine the relationship between pre-ICH statin use and ICH outcomes using data from the Registry of the Canadian Stroke Network, a large multicenter prospective cohort study of stroke care in 11 stroke centers in Ontario linked to postdischarge population-based mortality information. Our secondary objective was to determine whether statin discontinuation in the hospital was associated with worse clinical outcomes.
Methods
Phase III of the Registry of the Canadian Stroke Network began in July 2003 and prospectively enrolled consecutive patients presenting to 11 participating hospitals in Ontario, Canada, with a diagnosis of ischemic stroke, ICH, or transient ischemic attack. 16 -18 The Registry of the Canadian Stroke Network is "prescribed" by Ontario privacy legislation and is carried out without requirement for individual patient consent to avoid selection bias. 19 Research ethics board approval for the entire Registry of the Canadian Stroke Network project is provided by Sunnybrook Health Sciences Centre, and data collection at each participating hospital is provided by the local ethics board.
Between July 2003 and June 2008, 35 125 patients with transient ischemic attack, ischemic stroke, or any hemorrhagic stroke presented to the participating hospitals. Consecutive patients with confirmed ICH by brain imaging were deemed eligible for this study. Data were abstracted from the medical record by trained study personnel and included stroke type, demographics, medical history, preadmission medications, medications used in the hospital stay or at discharge, serum glucose on presentation, systolic blood pressure on presentation, in-hospital mortality, and modified Rankin Scale (mRS) score at discharge. Stroke severity was captured using the Canadian Neurological Scale (CNS). 20 Higher CNS scores indicate less severe stroke; the score ranges from 1 to 11.5. ICH volume was not measured, but presence of intraventricular extension was recorded. Thirty-day-and 6-month mortality data were available through linkage to provincial administrative databases.
For the primary objective, the exposure of interest was preadmission statin use, and primary outcomes were severity of stroke at presentation (measured by CNS), mRS at discharge, 30-day mortality, and 6-month mortality. When analyzed as the outcome in logistic regression analysis, CNS was dichotomized into mild (CNS Ͼ7) or severe (CNS Յ7) based on prior studies. 17, 18 Outcome at discharge was dichotomized as good (mRS 0 -3) or poor (mRS 4 -6) based on previously published studies. 17, 18, 21 We performed univariate analyses to explore potential associations between all covariates and primary outcomes using 2 test for categorical variables and 1-way analysis of variance for continuous variables. We then built separate multivariable logistic regression models for each primary outcome and included candidate variables from univariate testing with PՅ0. 10 . Variables eligible for inclusion were age, medical history (including history of hypertension and other vascular risk factors), blood pressure at admission, intraventricular hemorrhage, elevated international normalized ratio, glucose on admission, hemoglobin, platelet count, and preadmission use of antihypertensives, warfarin, or antiplatelet drugs. Nonsignificant variables (PϾ0.05) were subsequently eliminated in a backward-stepwise manner to create a minimal model. For the secondary objective, patients were divided into 4 groups: those with pre-ICH statin use who were prescribed statins during their admission (Group I or "on/on"), those with pre-ICH statin use in whom statins were discontinued during the hospital stay (Group II or "on/off"), pre-ICH statin-naive patients who were started on statins (Group III or "off/on"), and, as a reference group, statin-naive patients who were not started on statins (Group IV or "off/off"). Statins were counted as being continued or started if there was any documentation of statin use at any time during the admission or on discharge. Primary outcomes were discharge mRS, 30-day mortality, and 6-month mortality. We used 2 tests to compare outcomes among the 4 groups and to explore for possible associations with all covariates. We then built multivariable regression models as described previously with the statin grouping as exposure of interest using the "off/off" group as a reference category. To estimate the effect of early withdrawal of care on our findings, we performed 2 separate sensitivity analyses excluding: (1) all patients designated as palliative at any point during the admission; and (2) all patients who died within the first 48 hours of admission. Finally, to better understand the relationship among ICH severity, discontinuation of oral medications, and outcome, we also compared the frequency of discontinuation of oral hypoglycemic medications according to initial ICH severity.
Results
Between July 2003 and June 2008 2600 consecutive patients with primary ICH were admitted to a participating Registry of the Canadian Stroke Network hospital of whom 2510 (96.5%) could be linked to provincial health records. After excluding 44 repeat admissions for ICH during the study period, there were 2466 unique ICH admissions included in the analysis. Median age was 71 years, 53.6% were male, and 537 (22%) were taking statin medications (see Table 1 for detailed demographic information).
Univariate testing showed patients with preadmission statin use were older, were more likely to be taking antithrombotics or anticoagulants, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and were more likely to have a history of transient ischemic attack, prior ischemic stroke, atrial fibrillation, ICH, heart failure, myocardial infarction, or valvular heart disease (all PϽ0.01). Patients with preadmission statin use presented with lower systolic blood pressure (Pϭ0.10) and diastolic blood pressure (PϽ0.001) but higher glucose (PϽ0.001) and creatinine (PϽ0.001; Table 1 
97).
In multivariable analysis, prior statin use was associated with lower adjusted ORs for severe stroke at presentation (adjusted OR, 0.7; 95% CI, 0.6 -0.9;, Pϭ0.001), but not poor outcome at discharge (adjusted OR, 1.2; 95% CI, 0.9 -1.6; Pϭ0.14), 30-day mortality (adjusted OR, 0.9; 95% CI, 0.7-1.1; Pϭ0.36), or 6-month mortality (adjusted OR, 0.9; 95% CI, 0.7-1.2; Pϭ0.62). Online-only Data Supplement Table I (http://stroke.ahajournals.org) shows details of the final multivariable models. Because statins were independently associated with less severe stroke at presentation, which might mediate an effect of statins on improved outcome, we also performed post hoc analyses removing stroke severity and intraventricular hemorrhage from the models. This would be expected to reveal a significant statin effect if statins improve outcome by lowering initial stroke severity. In these post hoc analyses, there was no change in associations with discharge mRS or 30-day mortality, but preadmission statin use was associated with decreased 6-month mortality (adjusted OR, 0.74; 95% CI, 0.59 -0.93; Pϭ0.009).
Of the 537 patients who were taking statins, 158 (29%) had their statins discontinued on admission. Statin discontinuation was more common in patients with severe stroke symptoms; median CNS score was 7.5 in patients who had statins discontinued versus 3 in patients in whom statins were continued (online-only Data Supplement Table II) . Poor outcomes were most frequent in patients in whom statins were discontinued compared with patients in whom statins were continued, were started, or were not prescribed (Table  2) . Statin discontinuation was independently associated with poor functional outcome at discharge, higher 30-day mortality, and higher 6-month mortality compared with patients who were never on statins after controlling for stroke severity and other factors (Table 3) . However, the ORs for poor outcome were attenuated and only borderline significant after excluding patients treated palliatively at any point (Table 3) .
Oral hypoglycemics were used before ICH in 256 patients and were discontinued in 71 patients. Discontinuation of oral hypoglycemics was highly associated with discontinuation of statins in the 130 patients taking both before ICH (PϽ0.001). Similar to statin discontinuation, oral hypoglycemic discontinuation was associated with higher adjusted odds of 30-day mortality (OR, 9.0; 95% CI, 4.0 -20.3) and 6-month mortality (OR, 8.3; 95% CI, 3.8 -18.3).
Similar associations among statins, statin discontinuation, and outcome were seen in secondary post hoc analyses in which poor functional outcome was redefined as mRS 3 to 6, instead of mRS 4 to 6, except that the association between statin discontinuation and poor functional outcome was somewhat attenuated and no longer significant (adjusted OR, 1.7; 95% CI, 0.8 -3.6; online-only Data Supplement Table III) .
Discussion
Using a large well-characterized prospective cohort of patients with ICH, we found that pre-ICH statin use was associated with lower stroke severity at presentation but was not clearly associated with clinical outcome at discharge or 30-day and 6-month mortality. Statins were frequently discontinued during the hospital stay, and patients who had their statins discontinued had worse outcomes. Patients who were taking statins before admission and continued to take statins during the hospital stay had lower mortality but not better functional outcomes, whereas patients who had their statins discontinued had higher mortality and worse functional outcomes.
Interestingly, a multicenter study of 312 patients with ICH similarly reported pre-ICH statin use was associated with lower stroke severity but also showed lower mortality and discharge disability 6 ; 2 smaller single-center studies yielded similar results. 4, 7 However, these studies did not account for statin discontinuation and were either limited to in-hospital outcomes 6, 7 or were potentially biased due to significant loss to follow-up (36%). 4 A recent study with better follow-up failed to confirm an association between pre-ICH statin use and postdischarge outcomes. 8 
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In another large prospective cohort of 732 patients with ICH, pre-ICH statin use was associated with improved 90-day outcomes. 3 This study reported a low rate of statin discontinuation: 12% of patients as compared with 29% in our study. Thus, in that study, few patients were exposed to the effects of statin withdrawal on outcome. Indeed, both animal and human studies suggest that sudden cessation of statin medications may promote vascular injury through a variety of mechanisms including suppression of endothelial nitric oxide synthase, 10 generation of superoxide anions, 11 impaired endothelial relaxation, 11 loss of ischemic protection and thrombus inhibition, 12 and increased inflammatory activity. 13 Detrimental effects of statin withdrawal have been observed for ischemic stroke, 15 myocardial infarction, 22 and subarachnoid hemorrhage. 23 In our study we observed worse outcomes in patients with statin discontinuation. However, we also found evidence of confounding by indication such that statin discontinuation may have been a marker of higher stroke severity and underlying poor prognosis. Patients who had their statins On statins pre-and postadmission 1.3 ͓0.9-1.7͔
Statins discontinued at admission 1.8 ͓0.9-3.5͔
30-d mortality Entire cohort
Never on statin (reference) . . . Excluding death Ͻ48 h Never on statin (reference) . . . discontinued may have been more likely to have ongoing dysphagia precluding oral medication use or statins may have been stopped because of perceived poor prognosis. Conversely, lower mortality seen in patients who continued their statin medications may reflect the prescribing clinician's perception of a more favorable prognosis. Although the association between statin discontinuation and mortality persisted after controlling for stroke severity, the association was attenuated and only borderline significant when patients treated with palliative care were excluded. However, the exclusion of patients treated with palliative care may have biased the analysis toward a null result because patients who did poorly because of statin discontinuation may have been converted to palliative care and thus excluded. We found a similar relationship between hypoglycemic drug discontinuation and worse outcomes, similar to the relationship between statin discontinuation and worse outcomes, suggesting that inability to take oral medications in general may be a marker of poor prognosis. Ultimately, only data from randomized controlled trials can determine with certainty whether statin initiation or continuation is beneficial in acute ICH. The strengths of our study include its large size and prospective multicenter design. Furthermore, we were able to collect information regarding palliation and withdrawal of care, which are known confounders in ICH studies. 24, 25 However, our study also has several limitations and should be interpreted with caution. Similar to most other studies, we did not have information regarding dose, agent, adherence or duration of therapy, or data regarding statin use after discharge. We did not have baseline fasting lipid levels to assess the potential relationship with serum cholesterol levels and clinical outcome; however, serum lipids are not known predictors of ICH outcome. Furthermore, we did not have information regarding the aggressiveness of care in patients unlikely to recover from severe symptoms but who were not formally designated as palliative. Finally, we did not have access to brain imaging from the participating institutions and could not determine whether statins affect hematoma volume or expansion. The data in this study are observational in nature and should be considered hypothesis-generating.
Conclusions
Pre-ICH statin use was associated with lower stroke severity at presentation but not with discharge outcomes or 30-day and 6-month mortality. Statin discontinuation was independently associated with increased mortality when controlling for initial stroke severity but not after additionally excluding patients treated with palliative care at any point. There may be adverse biological effects of statin withdrawal that worsen prognosis as has been reported from a randomized trial in ischemic stroke. 15 However, in our study, we cannot conclude with certainty that statin discontinuation causes worse outcomes given the limits inherent to our observational study design. Randomized controlled trials of statin initiation and continuation will be needed to determine if statin exposure is beneficial in human ICH, as suggested by animal models. 1,2 
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